New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
16:27 EDTITMN, BRCM, NVDA, LOCK, TXN, AZN, CPB, MU, DTV, T, PFEOn The Fly: Closing Wrap
Stocks on Wall Street were higher following a trading day marked by light volume, a quiet economic calendar and two headline making M&A announcements. The averages began the day slightly below the flat line, but within minutes the Nasdaq and S&P 500 made it into positive ground. The Dow followed by the end of the morning, but the averages moved in a narrow range from there. Despite the range-bound trading, the market internals pointed to a pretty broad based move higher, with advancers ahead of declining stocks by almost 2 to 1. ECONOMIC EVENTS: In the U.S., no major domestic economic data was reported. COMPANY NEWS: AT&T (T) shares slid 36c, or 0.98%, to $36.38 after the company confirmed over the weekend that it has agreed to acquire DirecTV (DTV) for $95.00 per share, including $28.50 per share in cash and $66.50 per share in AT&T stock. After the announcement, analysts at Raymond James upgraded AT&T to Buy from Market Perform, noting that they do not expect another buyer to emerge for DirecTV. Meanwhile, DirecTV shares were downgraded to Equal Weight from Overweight at Evercore and to Hold from Buy at Wunderlich. Shares of DirecTV fell $1.53, or 1.77%, to $84.65 after the deal, which has been widely speculated about in the media in recent weeks, was confirmed... Also over the weekend, Pfizer (PFE) raised its bid for AstraZeneca (AZN), but the U.K. drugmaker again rejected this "final" takeover proposal. Shares of Pfizer rose 16c, or 0.55%, to $29.28 after the rejection, while shares of AstraZeneca trading in New York dropped $9.64, or 12.01%, to $70.64. MAJOR MOVERS: Among the notable gainers was InterMune (ITMN), which gained $4.61, or 13.44%, to $38.92 after reporting results from a study evaluating pirfenidone and having its shares upgraded to Outperform at Leerink. Also higher was NVIDIA (NVDA), which rose 58c, or 3.23%, to $18.54 after it was one of several semiconductor stock, along with Micron (MU), Texas Instruments (TXN), and Broadcom (BRCM), that were upgraded to Outperform from Sector Perform by RBC Capital in a note to investors earlier today. Among the noteworthy losers was LifeLock (LOCK), which fell $2.28, or 17.57%, to $10.70 after disclosing that the company is going to temporarily suspend its Wallet mobile application since it is not fully compliant with applicable payment card industry security standards. Also lower were shares of Campbell Soup (CPB), which dropped $1.06, or 2.35%, to $44.06 after the company reported mixed third quarter results and lowered its fiscal 2014 outlook. INDEXES: The Dow was up 20.55, or 0.12%, to 16,511.86, the Nasdaq was up 35.23, or 0.86%, to 4,125.81, and the S&P 500 was up 7.22, or 0.38%, to 1,885.08.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 >>
September 22, 2015
11:17 EDTLOCKLifeLock drops to lows following Probes Reporter post
Shares of LifeLock are down 4% after Probes Reporter mentioned the company in a blog post titled "Disclosure Insight: New Woes for LifeLock." Reference Link
10:00 EDTTAT&T commits to bringing broadband to over 37,00 homes, businesses in OH
AT&T has committed to extend broadband to more than 37,000 rural homes and businesses in Ohio over the next six years.
09:33 EDTMUActive equity options trading on open
Subscribe for More Information
08:23 EDTPFEAnalysts say buy select biotech stocks ahead of Clinton drug plan
Ahead of Presidential candidate Hillary Clinton laying out her plan to tackle "price gouging" in the specialty drug market at an event in Iowa later today, analysts at research firms Jefferies and Piper Jaffray are recommending select biotech stocks that they view as buys amid the weakness in the space. DEBATE: Biotech stocks broadly declined yesterday, with the NASDAQ Biotechnology index (IBB) sliding roughly 4.4%, after privately-held Turing Pharmaceuticals made headlines by enacting a 5,000% price increase on a 62-year-old drug that fights complication of AIDS and cancer. Furor around the sudden price hike for Turing's Daraprim reignited a debate around drug prices that previously embroiled costly Hepatitis C drugs including AbbVie's (ABBV) Viekira Pak and Gilead's (GILD) Sovaldi and Harvoni. The news also follows Presidential candidate Bernie Sanders issuing a letter in August to Valeant (VRX) and Pfizer's (PFE) Hospira, in which he requested information on the "enormous" price increases of two drugs Valeant acquired earlier in the year. Presidential candidate Hillary Clinton sent the debate to center stage yesterday by criticizing the "outrageous" prices of specialty drugs and promising to lay out a plan today to tackle "price gouging" in the specialty drug market. Clinton's proposal, which she'll outline in a speech in Iowa later today, would force pharmaceutical companies to reinvest their profits into research, allow for more generic and imported drugs and allow Medicare to negotiate lower drug costs and cap out-of-pocket expenses, according to details of the plan shared with USA Today. Zeke Emanuel, chair of medical ethics and health policy at the University of Pennsylvania, appeared on Nightly Business Report to discuss the problem of high drug prices and his suggested solutions. During his interview, Emanuel contended that giving Medicare the ability to negotiate drug prices may drive up prices for everyone else. DEFENSES: The Jefferies Biotechnology research team, led by Brian Abrahams, Eun Yang and Biren Amin, say their Washington D.C. consultants indicate the recent political rhetoric around drug pricing is unlikely to result in any substantive future policy changes that would impact biotech sector fundamentals. As such, they recommend using yesterday's selloff to buy select companies including Celgene (CELG), BioMarin (BMRN) and Alkermes (ALKS). Pricing concerns are nothing new, and will likely continue to be a headwind for the sector, the analysts tell investors in a research note. Hillary Clinton's proposal to combat drug pricing is likely to include "some combination of old and tried policies that have been out there for a few years," they write. The analysts also like shares of AMAG Pharmaceuticals (AMAG), Alder Biopharmaceuticals (ALDR) and Cempra (CEMP). Meanwhile, Piper Jaffray analyst Edward Tenthoff recommends buying shares of Vertex Pharmaceuticals (VRTX) following yesterday's selloff. Tenthoff believes that drugs like Vertex's Orkambi will maintain premium pricing because of the disease modifying value to patients and payors. Orkambi is approved to treat cystic fibrosis in patients 12 years and older. The analyst reiterates an Overweight rating on Vertex with a $163 price target. DOWNGRADE: Brean Capital analyst Difei Yang downgraded Horizon Pharma (HZNP) to Hold saying "unsettling recent developments" make the stock's premium valuation no longer justified. The public discussion on high drug prices is a negative for the company while its attempt to acquire Depomed (DEPO) is unlikely to result in a completed deal, Yang tells investors in a research note. Further, Horizon's prescription trends are showing weakness, said Yang, who views the stock as more risky than in the past. PRICE ACTION: Horizon closed yesterday down $2.93, or 9.2%, at $28.99, while Vertex dropped $5.97, or 4.8%, to $118.19. A number of the biggest stocks in biotechnology were also weak yesterday, with Gilead sliding about 2.5%, Amgen (AMGN) dropping 2.3%, Celgene declining 2.8% and Biogen (BIIB) falling more than 5.5%.
08:02 EDTAZNAstraZeneca to present 33 abstracts from respiratory disease portfolio at ERS
Subscribe for More Information
07:43 EDTAZN, PFEDrug stocks could be hurt by focus on pricing, says Oppenheimer
Subscribe for More Information
07:41 EDTMURaymond James to hold a conference
North American Equities Conference to be held in London, England on September 22.
07:17 EDTAZNAstraZeneca eyes crowd sourcing for better cancer drug cocktails, Reuters says
AstraZeneca's decision release preclinical data from over 50 of its medicines is "unprecedented" in scale and will speed up the hunt for tumor-fighting drug combinations, Reuters says. The company is aiming for a crowd sourcing initiative to help mix the future's cancer drug cocktails, the report says. Reference Link
06:40 EDTNVDA, TXN, MUChip sector deal size up substantially in 2015, WSJ reports
Subscribe for More Information
06:19 EDTAZN, PFEClinton to roll out plan to rein in prescription drug costs, USA Today reports
Subscribe for More Information
05:54 EDTMUDRAM price declines likely to continue through 2015, says Piper Jaffray
Subscribe for More Information
September 21, 2015
14:28 EDTAZN, PFETuring CEO says will not change Daraprim price despite criticism
Subscribe for More Information
11:24 EDTPFE, AZNHillary Clinton vows to take on 'outrageous' specialty drug pricing
Hillary Clinton, on the heels of a Wall Street Journal report detailing Turing Pharmaceuticals' price hike to $750 from $13.50 per pill of a drug called Daraprim which treats a life-threatening parasitic infection, vowed to lay out a plan tomorrow to take on what she calls "price gouging" of specialty drugs. The presidential nominee stated in a tweet, "Price gouging like this in the specialty drug market is outrageous. Tomorrow I'll lay out a plan to take it on." The iShares Nasdaq Biotechnology Index (IBB) moved lower following Clinton's tweet.
10:00 EDTMUOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Aquinox (AQXP) initiated with an Outperform at Leerink... Callon Petroleum (CPE) initiated with a Sector Perform at RBC Capital... Constellium (CSTM) initiated with an Outperform at Cowen... Energy Focus (EFOI) initiated with an Outperform at Oppenheimer... Galectin Therapeutics (GALT) initiated with a Buy at H.C. Wainwright... Helix Energy (HLX) initiated with a Market Perform at Cowen... IPG Photonics (IPGP) initiated with a Buy at DA Davidson... Intrexon (XON) initiated with a Buy at Stifel... Micron (MU) initiated with an Overweight at Barclays... New Relic (NEWR) initiated with an Overweight at Pacific Crest... Rice Energy (RICE) initiated with a Buy at Jefferies... SanDisk (SNDK) initiated with an Equal Weight at Barclays... Simmons First National (SFNC) initiated with a Neutral at Piper Jaffray... South State (SSB) initiated with a Neutral at Piper Jaffray... TerraForm Global (GLBL) initiated with a Hold at Deutsche Bank... Trimble (TRMB) initiated with an Equal Weight at Morgan Stanley... inContact (SAAS) initiated with a Buy at Lake Street.
08:03 EDTPFEPfizer says two Phase 3 tofacitinib 10mg trials met primary endpoints
Subscribe for More Information
06:34 EDTTSamsung may be planning leasing program for Galaxy phones, Forbes reports
Samsung (SSNLF) is rumored to be planning to launch a leasing program for its Galaxy phones in the U.S., similar to the program Apple (AAPL) recently announced, Forbes reports, citing an industry executive with knowledge of Samsung's plans. According to the source, Samsung could launch the leasing program in the next few months. Apple's iPhone Upgrade Program encourages consumers to buy iPhones directly from the Apple Store instead of going through carriers, the publication notes. Publicly traded wireless carriers include AT&T (T), Verizon (VZ), Sprint (S) and T-Mobile US (TMUS). Reference Link
06:07 EDTMUServer DRAM prices are down 15% since beginning of Q3, DigiTimes says
DRAMeXchange said average contract prices for server DRAM chips are down 15% since the beginning of Q3 due to weak demand, reports DigiTimes. DRAMeXchange added that shipments of branded enterprise servers have decelerated and dropped due to a weak global economy and currency rate fluctuations. Reference Link
05:44 EDTMUSanDisk initiated with an Equal Weight at Barclays
Subscribe for More Information
05:41 EDTMUMicron initiated with an Overweight at Barclays
Barclays analyst Blayne Curtis started shares of Micron (MU) with an Overweight rating and $20 price target. Curtis believes near-term risk from weak DRAM demand is priced into the stock at current levels. He thinks 2016 will be improved demand and pricing. The analyst also initiated this morning shares of SanDisk (SNDK) with an Equal Weight rating.
September 20, 2015
21:07 EDTBRCM, MUDialog to acquire Atmel in move towards Internet of Things
Atmel (ATML) reached an agreement Sunday to be acquired by Dialog Semiconductor in a deal valued at approximately $4.6B, or the equivalent of $10.42 per Atmel share. Jalal Bagherli, CEO of U.K.-based Dialog, remarked that the combined company will be "a diversified, high-growth market leader" in chips for mobile devices, connected vehicles, and the Internet of Things. In a subsequent Bloomberg interview regarding the deal, Bagherli explained, "We passed the computing era, we're at the height of the mobile era, and we're about to enter the IoT era." The news comes after several semiconductor mergers in 2015 amid slowing growth and saturated markets, with Intel (INTC) agreeing in June to acquire Altera (ALTR) and Avago (AVGO) striking a deal in May for Broadcom (BRCM). Note also China's apparent desire to control companies in the space, evidenced by state-owned firms China Electronics Corp. and Tsinghua's respective pursuits of Atmel and Micron (MU).
1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use